CannaPharmaRx Inc.

11/17/2026 | Press release | Distributed by Public on 11/17/2026 07:10

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of the Company's financial condition and results of operations as at and for the three and nine months ended September 30, 2026 and 2025 should be read together with the Company's financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and related footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2025.

We caution readers regarding certain forward-looking statements in the following discussion and elsewhere in this Report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward-looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on our behalf. Except as required by law, we disclaim any obligation to update forward-looking statements.

Forward-Looking Statements

This Quarterly Report on Form 10-Q includes a number of "forward-looking statements" including statements concerning anticipated financial results and developments of our operations in future periods that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 as filed with the U.S. Securities and Exchange Commission (the "SEC") on March 31, 2026, any of which may cause our company's or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements. These risks and factors include, by way of example and without limitation:

· risks associated with the Company's history of losses and need for additional financing,
· risks associated with increased costs affecting its financial condition,
· risks associated with uninsured risks,
· risks associated with governmental and environmental regulations,
· risks associated with future legislation regarding the cannabis industry and climate change,
· risks associated with cybersecurity and cyber-attacks,
· risks associated with legal matters and claims against the Company,
· risks related to economic conditions,
· risks related to our ability to manage growth,
· risks related to our dependence on key personnel,
· risks related to our SEC filing history, and
· risks related to our securities.

This list is not exhaustive of the factors that may affect the Company's forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those described in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Except as required by law, the Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. The Company qualifies all the forward-looking statements contained in this Quarterly Report on Form 10-Q by the foregoing cautionary statements.

Readers are urged to carefully review and consider the various disclosures made by us in this Report and in our other reports filed with the SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.

OVERVIEW AND HISTORY

As used in this Quarterly Report on Form 10-Q, unless otherwise indicated, the terms "CannaPharmaRX," the "Company," "we," "us," and "our" refer to CannaPharmaRX, Inc. and our wholly owned subsidiaries. Unless otherwise specified, all dollar amounts are expressed in United States dollars ("USD"). We specialize in the acquisition, development, and operation of cannabis cultivation facilities in Canada. We were originally incorporated in Colorado in August 1998 as Network Acquisitions, Inc. In October 2014, we changed our legal name to CannaPharmaRx, Inc. We currently focus on producing high-quality medical cannabis and craft cannabis products. Our principal executive office is located at 4439 Township Rd 304, Mountain View County, Alberta, Canada T0M 0R0. Our expansion plans are subject to obtaining additional financing; we do not currently have sufficient cash resources to fund ongoing operations.

On January 1, 2022, we entered into a lease for the use of a 55,000 square foot facility located in Cremona, Alberta, Canada (the "Facility"). The lease was amended and restated effective January 1, 2025 for a term of seventeen years expiring December 31, 2041. During 2022, we recommissioned the Facility into an indoor cannabis farm with 10 growing rooms and one drying and packing room. The Facility now has six growing rooms and one drying and packing room in operation and the Company plans to increase capacity over the next one to two years to open a second drying and packing room and to operate all 10 growing rooms.

We received an operating license from Health Canada on December 9, 2022, and a cannabis license from the Canada Revenue Agency on December 22, 2022 and commenced cannabis production during the year ended December 31, 2023. Our common shares are traded on the OTC Pink Sheets under the trading symbol "CPMD."

Growth strategy

We plan to grow by increasing capacity at the Facility to support cannabis sales in European markets, with a focus on Germany and Israel. To support this initiative, we intend to expand operations at the Facility from six active growing rooms to all 10 growing rooms over the next one to two years, open a second drying and packing room, build and develop a sales network in Germany and Israel, and apply for European Union Good Manufacturing Practices ("EU-GMP") certification. Currently, we are required to send our cannabis to a third-party European intermediary for packaging in compliance with EU-GMP standards. Once certified, we expect to eliminate this step and ship directly to countries within the European Union ("EU"), reducing overall costs and shipping times.

To facilitate our growth strategy, on November 22, 2023, we entered into an agreement with LTB Management, LLC ("LTB") in support of building and developing a sales network in the EU and obtaining access to LTB's e-commerce technology related to online sales of cannabis in the EU. Under this agreement, we obtained 100 Class B units of LTB in exchange for 27,224,962 share purchase warrants, each entitling the holders to purchase one common share at $0.02 per share until November 22, 2028; $3,000,000 in promissory notes payable to the LTB; and 100,000 Series C preferred shares of our company. Contingent consideration included a quarterly true-up of LTB's preferred share proportional ownership to 33% of the outstanding shares of our common shares, and an earn out whereby LTB can earn up to an additional 12% pro-rata preferred share proportional ownership (which, if earned, will result in the true-up increasing by the pro-rata preferred share proportional ownership earned) based on our reaching a threshold of $2,500,000 in annual revenue (pro-rated) at any time within 24 months of the agreement date. The earn-out period expired on November 22, 2025. As at September 30, 2026, the Company has an obligation to issue shares to Mr. Tal and Koze under the true-up, valued at $908,462 (see Note 5 of the condensed interim consolidated financial statements). As of December 31, 2025, management concluded the investment was fully impaired and recognized an impairment loss of $4,518,127.

OUR PRODUCTS

Cannabis Products

We produce and sell dried cannabis flower, which we package for sale as dried flower, trim, and shake. We market dried flower primarily for medicinal use. Dried flower remains a core product category across global cannabis markets, and we therefore maintain a strong focus on consistent, high-quality cultivation.

Going Concern

Substantial doubt exists as to our ability to continue as a going concern based on the fact that we do not have adequate working capital to finance our day-to-day operations. For the three and nine months ended September 30, 2026, we reported $137,705 and $1,041,385, respectively (2025 - $656,606 and $1,223,533, respectively) in revenue. As at September 30, 2026, we had cash of $32,037, a working capital deficiency of $30,929,128 and an accumulated deficit of $113,961,237. Additionally, for the nine months ended September 30, 2026, we used $537,675 (2025 - $1,850,544) of cash in operating activities.

These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management plans to address this uncertainty by seeking additional capital in the near term, primarily through equity issuances or other financing instruments. Given the Company's status as a penny stock issuer on the OTC Markets, its constrained liquidity and solvency position, and the limited availability of third-party financing, management expects that a significant portion of any additional funding will likely need to come from related parties. There can be no assurance that the Company will complete additional financings or collaboration transactions, or that any financing will be available on commercially reasonable terms or in amounts sufficient to meet its obligations and support its business plan. If the Company does not obtain additional financing on a timely basis, it may be required to scale back or cease operations. Any issuance of additional equity securities could materially dilute existing shareholders. In addition, pending litigation and other legal proceedings could adversely affect the Company's liquidity, results of operations, and ability to continue as a going concern if resolved unfavorably.

On March 17, 2025, the Company and its subsidiary, 2323414 Alberta Ltd. ("Alberta Ltd."), which conducts the Company's principal business activities, including the cultivation, processing, and distribution of cannabis, entered into a security and royalty agreement with Koze Investments LLC ("Koze"), a California limited liability company engaged in financing and investment activities. Koze has been considered a related party since March 11, 2025, the date on which its manager, Elliot Zemel, was appointed as a director of the Company. Under the agreement, the Company is required to pay a royalty on cannabis product sales from the prior month, with the applicable rate increasing if royalty payments are not made on time. The agreement provides that a default occurs if Alberta Ltd. fails to make royalty or lease payments for three consecutive months or for any four months within a rolling six-month period. As collateral, the Company granted Koze a security interest in its entire ownership interest in Alberta Ltd., which will remain in place until all obligations are fully satisfied. As at September 30, 2026, Alberta Ltd. was in default of its payment obligations, and Koze agreed to forbear from exercising its rights over that ownership interest until August 31, 2026. The forbearance period expired on August 31, 2026. See Note 2 and Note 9 to the condensed interim consolidated financial statements. The Company also incurred royalty expense under the agreement and recorded a related liability in royalty payable as at September 30, 2026.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

Revenue

During the three months ended September 30, 2026 and 2025, the Company reported revenue of $137,705 and $656,606, respectively. The decrease primarily reflects lower sales volumes in the current period, with no sales to Cantek in the current quarter, as discussed under "Related party transactions."

Cost of Goods Sold

During the three months ended September 30, 2026 and 2025, the Company reported cost of goods sold of $415,487 and $1,030,313, respectively. The decrease was primarily due to lower sales volumes and lower inventory impairment charges in the current period. Included in cost of goods sold for the three months ended September 30, 2026 and 2025 are losses on the impairment of inventory of $284,632 and $393,796, respectively, primarily based on factors including expected yield of work-in-progress inventory and corresponding market prices.

Gross Loss

During the three months ended September 30, 2026 and 2025, the Company reported a gross loss of $277,782 and $373,707, respectively. The decrease in gross loss primarily reflects the decrease in cost of goods sold, including lower inventory impairment charges, which more than offset the decrease in revenue in the current period.

Operating Expenses

A summary of the Company's operating expenses is as follows:

Three months ended
September 30,
2026 2025
General and administrative $ 159,445 $ 211,737
Professional fees 66,193 115,990
Royalty expense 29,523 234,212
$ 255,161 $ 561,939

During the three months ended September 30, 2026 and 2025, the Company's operating expenses consisted primarily of general and administrative expenses, professional fees associated with the costs for services or employees in finance, accounting, sales, administrative activities and the compliance of a public company, and royalty expense. Overall operating expenses for the three months ended September 30, 2026 were $255,161 compared to operating expenses of $561,939 in the prior year comparable period, a decrease of $306,778. The decrease is primarily attributable to the following:

· A $204,689 decrease in royalty expense, reflecting lower grams sold in the current period than in the prior-year comparable period under the Koze agreement entered into on March 17, 2025.
· A $49,797 decrease in professional fees, primarily reflecting lower accounting and legal fees in the current period.
· A $52,292 decrease in general and administrative expenses, primarily reflecting lower advertising and marketing, travel and property tax costs in the current period.

Other income (expenses)

A summary of the Company's other income and expenses is as follows:

Three months ended
September 30,
2026 2025
Change in the fair value of derivative conversion feature $ 1,728,677 $ 7,296
Change in the fair value of obligation to issue shares 181,693 168,355
Foreign exchange gain (loss) 637 (24,243 )
Interest expense (458,291 ) (506,331 )
Imputed interest expense (274,357 ) (187,242 )
$ 1,178,359 $ (542,165 )

Other income totaled $1,178,359 for the three months ended September 30, 2026, compared with other expenses of $542,165 in the comparable 2025 period, primarily due to the following:

· Change in the fair value of derivative conversion feature arising from variably priced convertible notes was a gain of $1,728,677 compared to a gain of $7,296 in the prior year comparable period. The primary drivers of these fair value changes were changes in the Company's share price and peer-based expected volatility as the Company's common shares trade infrequently on the OTC Markets, the remaining term to expiration of the convertible notes and the conversion feature's exercise price.
· Change in the fair value of obligation to issue shares was a gain of $181,693 compared to a gain of $168,355 in the 2025 comparable period resulting from remeasurement of the obligation to issue shares.

The increase in other income was partially offset by the following:

· A $87,115 increase in imputed interest expense due to debt modification of certain loans to related parties, which resulted in a remeasurement of the liabilities and recognition of additional imputed interest expense.
· A $48,040 decrease in interest expense, which partially offset the increase in imputed interest expense, is primarily attributable to a reduction in the interest rate for certain loans to related parties, pursuant to a debt modification agreement entered into by the Company with those related parties.

Net Income (Loss)

As a result of the foregoing, during the three months ended September 30, 2026, the Company recorded net income of $645,416 or $0.00 per share basic and $(0.00) diluted compared to a net loss of $1,477,811 or $(0.00) per share in the 2025 comparable quarter. The quarter's net income reflects non-cash fair value gains of $1,728,677 on derivative conversion features and $181,693 on the obligation to issue shares, notwithstanding an operating loss of $532,943. These gains did not provide cash to fund operations.

RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

Revenue

During the nine months ended September 30, 2026 and 2025, the Company reported revenue of $1,041,385 and $1,223,533, respectively. The decrease primarily reflects lower sales volumes in the current period. As discussed under "Related party transactions," related-party revenue from Cantek was $903,680 in 2026 compared with $231,608 in the prior-year comparable period.

Cost of Goods Sold

During the nine months ended September 30, 2026 and 2025, the Company reported cost of goods sold of $1,734,527 and $2,591,451 respectively. The decrease was primarily due to lower sales volumes and lower inventory impairment charges in the current period. Included in cost of goods sold for the nine months ended September 30, 2026 and 2025 are losses on the impairment of inventory of $864,567 and $1,310,393, respectively, primarily based on factors including expected yield of work-in-progress inventory and corresponding market prices.

Gross Loss

During the nine months ended September 30, 2026 and 2025, the Company reported a gross loss of $693,142 and $1,367,918, respectively. The decrease in gross loss primarily reflects the decrease in cost of goods sold, including lower inventory impairment charges, which more than offset the decrease in revenue in the current period.

Operating Expenses

A summary of the Company's operating expenses is as follows:

Nine months ended
September 30,
2026 2025
General and administrative $ 410,537 $ 455,936
Professional fees 265,820 340,546
Royalty expense 224,618 289,811
$ 900,975 $ 1,086,293

During the nine months ended September 30, 2026 and 2025, the Company's operating expenses consisted primarily of general and administrative expenses, professional fees associated with the costs for services or employees in finance, accounting, sales, administrative activities and the compliance of a public company, and royalty expense. Overall operating expenses for the nine months ended September 30, 2026 were $900,975 compared to operating expenses of $1,086,293 in the prior year comparable period, a decrease of $185,318. The decrease is primarily attributable to the following:

· A $65,193 decrease in royalty expense, reflecting lower grams sold in the current period than in the prior-year comparable period under the Koze agreement entered into on March 17, 2025.
· A $74,726 decrease in professional fees, primarily reflecting lower accounting and legal fees in the current period.
· A $45,399 decrease in general and administrative expenses, primarily reflecting lower advertising and marketing and travel costs, partially offset by higher selling and distribution costs.

Other income (expenses)

A summary of the Company's other income and expenses is as follows:

Nine months ended
September 30,
2026 2025
Change in the fair value of derivative conversion feature $ 929,977 $ 602,569
Change in the fair value of obligation to issue shares 1,258,219 2,095,299
Foreign exchange gain (loss) (77,448 ) 71,084
Interest expense (1,282,916 ) (1,779,362 )
Imputed interest expense (879,362 ) (187,242 )
Other expense - (1,930,000 )
$ (51,530 ) $ (1,127,652 )

Other expenses totaled $51,530 for the nine months ended September 30, 2026 compared with $1,127,652 in the comparable 2025 period. The decrease was primarily due to the following:

· Change in the fair value of derivative conversion feature arising from variably priced convertible notes was a gain of $929,977 compared to a gain of $602,569 in the prior year comparable period. The primary drivers of these fair value changes were changes in the Company's share price and peer-based expected volatility as the Company's common shares trade infrequently on the OTC Markets, the remaining term to expiration of the convertible notes and the conversion feature's exercise price.
· A $496,446 decrease in interest expense is primarily attributable to a reduction in the interest rate for certain loans to related parties, pursuant to a debt modification agreement entered into by the Company with those related parties.
· A non-cash one-time adjustment of $1,930,000 in the prior year comparable period was made to lease-related rent expense due to a clarification in the interpretation of the lease terms between management and Formosa, with no comparable charge in the current period.

The decrease in other expenses was partially offset by the following:

· A $692,120 increase in imputed interest expense due to debt modification of certain loans to related parties, which resulted in a remeasurement of the liabilities and recognition of additional imputed interest expense.
· Change in the fair value of obligation to issue shares was a gain of $1,258,219 compared to a gain of $2,095,299 in the 2025 comparable period resulting from remeasurement of the obligation to issue shares.

Net Loss

As a result of the foregoing, during the nine months ended September 30, 2026, the Company recorded a net loss of $1,645,647 or ($0.00) per share compared to a net loss of $3,581,863 or ($0.01) per share in the 2025 comparable period.

LIQUIDITY AND CAPITAL RESOURCES

As at September 30, 2026, the Company had $32,037 in cash, compared with $1,804 as at December 31, 2025, and a working capital deficiency of $30,929,128 compared with $30,278,570 as at December 31, 2025. During the nine months ended September 30, 2026, the Company's funding was primarily attributable to advances made by Koze, a related party, directly to the Company's suppliers. During the three and nine months ended September 30, 2026, Koze made payments of $474,056 and $1,432,492, respectively, directly to the Company's suppliers. In addition, Koze received $nil and $785,105 respectively directly from customers. These advances and customer collections relate to an ongoing funding arrangement under which Koze funds additional amounts from time to time based on the Company's operational needs, has no stated limit, and may be discontinued by Koze at any time.

The Company is dependent on Koze to continue funding its operations. As at September 30, 2026, loans payable to related parties totaled $14,382,683, all of which is classified as current. The Koze and Mr. Tal notes mature on December 31, 2026, and Alberta Ltd. is in default of its royalty payment obligations under the security and royalty agreement with Koze. Koze's forbearance from exercising its rights over the ownership interest expired on August 31, 2026. See Note 9 to the condensed interim consolidated financial statements for events subsequent to period end relating to the forbearance and note maturities.

Based on current financial projections, the Company does not have sufficient existing cash resources to fund its current operations. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern. Management intends to address these liquidity challenges through debt financings and/or raise additional funding through equity financing to support ongoing operating expenses and working capital needs. There is no assurance that these events will be satisfactorily completed or at terms acceptable to the Company and therefore, the Company is heavily reliant on funding from related parties. If the Company is unable to secure adequate financing or otherwise successfully implement its plans, it may be required to significantly reduce or curtail its operations, or cease operations entirely. Any issuance of equity securities to raise capital could result in substantial dilution to existing shareholders. Certain borrowings are secured by the Company's assets, including equipment and receivables. In the event of default, lenders may have the right to seize collateralized assets.

The summary of the Company's cash flows is as follows:

Nine months ended
September 30,
2026 2025
Cash used in operating activities $ (537,675 ) $ (1,850,544 )
Cash used in investing activities (55,706 ) -
Cash provided by financing activities 624,069 1,849,315
Effect of exchange rate changes on cash (455 ) -
Net change in cash $ 30,233 $ (1,229 )

Cash flows from operating activities

Cash used in operating activities for the nine months ended September 30, 2026 decreased by $1,312,869 compared to the prior year comparable period, primarily due to higher cash paid by related parties directly to suppliers in the current period.

Cash flows from investing activities

Cash used in investing activities for the nine months ended September 30, 2026 was $55,706 compared to $nil in the prior year comparable period, due to purchase of equipment.

Cash flows from financing activities

Cash provided by financing activities for the nine months ended September 30, 2026 was $624,069 compared to $1,849,315 in the prior year comparable period, due to proceeds from related party loans.

Related party transactions

Revenue

During the three and nine months ended September 30, 2026, the Company recognized revenue of $nil and $903,680, respectively (2025 - $nil and $231,608, respectively) from the related party D.N.S. CANTEK 2019 LTD ("Cantek"), an Israeli limited corporation owned 100% by Koze, and for which Mr. Tal serves as a financial advisor.

A summary of the Company's average selling prices by market is as follows:

Average Price per Gram (CAD)*
Market Premium Batches Medium Batches
Germany 2.05 1.60
Israel 2.00 1.60-1.80
Canada 2.00 1.10-1.50
Portugal 1.80-2.00 0.80-1.50

* Batches with THC concentrations below 20% are generally sold at lower average prices compared to higher-THC batches.

Lease expense

The Company has a lease with Formosa, which became a related party upon the appointment of its manager, Elliot Zemel, as a director of the Company on March 11, 2025.

Three months ended
September 30,
Nine months ended
September 30,
2026 2025 2026 2025
Lease expense (1) $ 267,934 $ 272,232 $ 812,204 $ 804,457
Interest expense related to rent in default, associated with unpaid lease payments 177,471 145,858 508,440 435,600
Total $ 445,405 $ 418,090 $ 1,320,644 $ 1,240,057
(1) Lease expense above represents the contractual rent payable under the lease. The lease cost charged to production for the three and nine months ended September 30, 2026 was $260,986 and $791,047, respectively, of which the idle-capacity share is presented in general and administrative expenses and the balance is included in cost of goods sold.

Professional fees

Three months ended
September 30,
Nine months ended
September 30,
2026 2025 2026 2025
Invictus Accounting Group LLP ("Invictus") (1) $ 41,659 $ 42,119 $ 111,647 $ 168,938
Fabian Vancott (2) - 4,600 11,925 51,787
Total $ 41,659 $ 46,719 $ 123,572 $ 220,725
(1) Invictus provides part-time CFO, financial reporting, and bookkeeping services to the Company. Mr. Oliver Foeste is the Managing Partner of Invictus.
(2) Anthony Panek who is a partner in Fabian Vancott, is also a director of the Company.

Royalty expense

On March 17, 2025, the Company and Alberta Ltd. entered into the Royalty Agreement, pursuant to which the Company is required to pay a royalty of CAD $0.20 per gram on cannabis product sales, payable at the beginning of the month for the previous month, as additional consideration related to the lease with Formosa. Immediately upon failure to pay the royalty when due, the royalty rate increases to CAD $0.40 per gram sold for the applicable month. As at September 30, 2026, Alberta Ltd. was in default of its payment obligations, and Koze agreed to forbear from exercising its rights over the ownership interest until August 31, 2026. The forbearance period expired on August 31, 2026. See Note 9 to the condensed interim consolidated financial statements for events subsequent to period end relating to the forbearance and note maturities.

During the three and nine months ended September 30, 2026, the Company sold 102,244 and 773,299 grams of cannabis products, respectively, (2025 - 806,568 and 998,952 grams respectively) and for the three and nine months ended September 30, 2026, the Company incurred a royalty expense of $29,523 and $224,618, respectively (2025 - $234,212 and $289,811, respectively) which is calculated using a royalty rate of CAD $0.40 per gram sold since no royalty payments have been made by the Company

Interest expense

Three months ended
September 30,
Nine months ended
September 30,
2026 2025 2026 2025
Promissory and convertible notes with Mr. Tal $ 11,734 $ 17,016 $ 32,402 $ 71,154
Promissory and convertible notes with Koze 189,176 288,597 496,236 1,109,554
Promissory note with Formosa 31,187 26,459 87,386 75,120
Rent in default with Formosa 177,471 145,858 508,440 435,600
Total $ 409,568 $ 477,930 $ 1,124,464 $ 1,691,428

Imputed interest expense

Three months ended
September 30,
Nine months ended
September 30,
2026 2025 2026 2025
Promissory and convertible notes with Mr. Tal $ 18,552 $ 12,135 $ 50,914 $ 12,135
Promissory and convertible notes with Koze 204,171 145,587 683,771 145,587
Promissory note with Formosa 51,634 29,520 144,677 29,520
Total $ 274,357 $ 187,242 $ 879,362 $ 187,242

Other expense

During the nine months ended September 30, 2025, the Company made a non-cash one-time adjustment of $1,930,000 to lease-related rent expense due to a clarification in the interpretation of the lease terms for the Facility, which is recorded as other expense.

Amounts due to related parties

September 30,

2026

December 31,
2025
Accounts payable and accrued liabilities $ 6,121,882 $ 5,416,889
Accrued interest 2,150,400 1,352,899
Loans payable to related parties 14,382,683 13,116,485
Royalty payable 513,129 305,492
Liability for right-of-use building 5,771,851 6,034,080
Obligation to issue shares 908,462 2,166,681
Total $ 29,848,407 $ 28,392,526

Accounts payable and accrued liabilities

A summary of accounts payable and accrued liabilities including balances owing to related parties is as follows:

September 30,

2026

December 31,
2025
Outstanding lease payments to Formosa $ 5,041,794 $ 4,283,706
Part-time CFO, financial reporting, and bookkeeping services outstanding to Invictus 101,747 146,306
Unpaid directors' fees for 2021 through 2023 to Rick Orman, a former director of the Company (1) 319,279 319,279
Unpaid salary and expense reimbursement to Dominic Colvin, a director of the Company, for his service as Chief Executive Officer from 2019 through 2022 (1) 533,202 551,953
Unpaid legal fees to Fabian Vancott 125,860 115,645
Total $ 6,121,882 $ 5,416,889
(1) See "Claims by Current and Former Directors" in Note 6 to the condensed interim consolidated financial statements.

Loans payable to related parties

On August 7, 2025, the Company entered into an agreement (the "Debt Modification") with Mr. Tal, Koze and Formosa to amend the annual interest rates on all outstanding promissory and convertible notes held by them to 6%, compounding annually. This was deemed to be a substantial modification of the terms of the agreements and was accounted for as an extinguishment of the promissory and convertible notes and recognition of new notes at the new 6% rate. The term to maturity was unchanged. In connection with the issuance of the new notes resulting from the Debt Modification, the Company determined that the market interest rate for similar instruments was 15%. Accordingly, the debt was recorded at a discount to reflect this effective interest rate, with the discount amortized to imputed interest expense over the term of the debt using the effective interest method.

Mr. Tal and Koze are related parties of the Company by virtue of their equity rights. During 2026 the maturity date of all outstanding promissory and convertible notes held by them was extended to December 31, 2026 (the "2026 Debt Amendment"). The stated annual interest rate of 6% and the 15% market rate used to impute interest were unchanged by the 2026 Debt Amendment. Because the notes bear interest below the market rate and are held by shareholders of the Company, the discount arising on initial imputation was recognized as a capital contribution to additional paid-in capital, rather than in the condensed interim consolidated statements of operations and comprehensive income (loss).

A summary of the carrying amounts on the loans payable to related parties is as follows:

September 30,

2026

December 31,
2025
PLC International Investments Inc. ("PLC") (a) $ 12,995 $ 13,430
Koze Lucky Tackle Box Management, LLC ("LTB") (b) 3,136,805 3,093,478
Koze A (c) 1,797,914 1,400,243
Koze B (d) 6,282,535 5,529,686
Koze C (e) 344,845 343,701
Koze convertible note ("Koze CN") (f) 131,735 131,298
Mr. Tal LTB (g) 375,487 447,647
Mr. Tal convertible note ("Mr. Tal CN") (h) 305,260 306,571
Formosa (i) 1,995,107 1,850,431
Total $ 14,382,683 $ 13,116,485
a) PLC

Interest-free loan from PLC, a company owned by Dominic Colvin, a director of the Company.

b) Koze LTB

On November 22, 2023, the Company entered into promissory notes of $2,550,000 with Koze, as part of the LTB transaction, bearing interest at 13% per annum. Originally due on November 22, 2024, the maturity date for this note was extended to December 31, 2025, by agreement with Koze. On March 18, 2026, Mr. Tal and Koze agreed to extend the maturity date of the promissory notes to December 31, 2026.

As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $2,550,000 and $555,406, respectively, were extinguished. A new note ("Koze LTB") of $2,978,661 bearing 6% interest, compounding annually, was recognized resulting in a gain of $126,745 from extinguishment, recorded directly to additional paid-in capital.

As a result of the 2026 Debt Amendment, a discounting effect of $244,792 was recognized as a capital contribution to additional paid-in capital.

c) Koze A

On May 25, 2023, the Company entered into a promissory note with Koze, bearing annual interest at 24% compounded monthly, to fund certain documented expenses.

As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $849,278 and $443,339, respectively, were extinguished. A new note ("Koze A") of $1,134,669 bearing 6% interest, compounding annually, was recognized resulting in a gain of $157,949 from extinguishment, recorded directly to additional paid-in capital.

As a result of the 2026 Debt Amendment, a discounting effect of $124,239 was recognized as a capital contribution to additional paid-in capital.

During the three and nine months ended September 30, 2026, the Company had $137,995 and $401,976 in net additions to the promissory note.

d) Koze B

On May 25, 2023, the Company entered into another promissory note with Koze, bearing annual interest at 24% compounded monthly, to fund the Company for certain documented expenses.

As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $4,040,474 and $1,366,780, respectively, were extinguished. A new note ("Koze B") of $4,767,106 bearing 6% interest, compounding annually, was recognized resulting in a gain of $640,148 from extinguishment, recorded directly to additional paid-in capital.

As a result of the 2026 Debt Amendment, a discounting effect of $473,849 was recognized as a capital contribution to additional paid-in capital.

During the three and nine months ended September 30, 2026, the Company had $600,568 and $1,731,365 in additions on the promissory note. During the three and nine months ended September 30, 2026, the Company had $nil and $785,105 in repayments on the promissory note.

e) Koze C

On February 8, 2024, the Company entered into another promissory note with Koze, bearing annual interest at 24% compounded monthly.

As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $275,000 and $97,403, respectively, were extinguished. A new note ("Koze C") of $330,551 bearing 6% interest, compounding annually, was recognized resulting in a gain of $41,852 from extinguishment, recorded directly to additional paid-in capital.

As a result of the 2026 Debt Amendment, a discounting effect of $30,562 was recognized as a capital contribution to additional paid-in capital.

f) Koze CN

The Company has a convertible note with Koze, bearing annual interest at 24%. As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $68,555 and $75,714, respectively, were extinguished. A new note, Koze CN, of $126,275 bearing 6% interest, compounding annually, was recognized resulting in a gain of $17,995 from extinguishment, recorded directly to additional paid-in capital.

As a result of the 2026 Debt Amendment, a discounting effect of $11,675 was recognized as a capital contribution to additional paid-in capital.

g) Mr. Tal LTB

On November 22, 2023, the Company entered into a promissory note of $450,000 with Mr. Tal as part of the LTB transaction, bearing interest at 13% per annum. Originally due on November 22, 2024, the maturity date for this note was extended to December 31, 2025, by agreement with Mr. Tal. On March 18, 2026, Mr. Tal and Koze agreed to extend the maturity date of the promissory notes to December 31, 2026.

As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $438,296 and $89,768, respectively, were extinguished. A new note ("Mr. Tal LTB") of $507,422 bearing 6% interest, compounding annually, was recognized resulting in a gain of $20,641 from extinguishment, recorded directly to additional paid-in capital.

As a result of the 2026 Debt Amendment, a discounting effect of $39,888 was recognized as a capital contribution to additional paid-in capital.

During the three and nine months ended September 30, 2026, the Company made repayments of $46,778 and $76,778 on the promissory note and accrued interest.

h) Mr. Tal CN

The Company had a convertible note with Mr. Tal, bearing annual interest at 24%.

As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $212,555 and $121,427, respectively, were extinguished. A new note, Mr. Tal CN, of $294,850 bearing 6% interest, compounding annually, was recognized resulting in a gain of $39,132 from extinguishment, recorded directly to additional paid-in capital.

As a result of the 2026 Debt Amendment, a discounting effect of $29,435 was recognized as a capital contribution to additional paid-in capital.

i) Formosa

On January 1, 2025, the Company entered into a promissory note with Formosa in the amount of $1,930,000, bearing interest at 5% per annum, with respect to a one-time adjustment made to lease-related rent expense due to a clarification in the interpretation of the lease terms for the Facility.

As a result of the Debt Modification, principal and accrued interest outstanding related to the note as at August 7, 2025 of $1,930,000 and $58,098, respectively, were extinguished. A new note of $1,775,707 bearing 6% interest, compounding annually, was recognized resulting in a gain of $212,391 from extinguishment, recorded directly to additional paid-in capital.

A summary of the accrued interest of the Company's loans payable to related parties is as follows:

September 30,

2026

December 31,
2025
Koze LTB $ 135,427 $ 76,062
Koze A 72,646 31,070
Koze B 260,523 132,215
Koze C 14,888 8,394
Koze CN 5,687 3,207
Mr. Tal LTB 16,882 11,887
Mr. Tal CN 13,184 7,488
Promissory note with Formosa 132,795 45,396
$ 652,032 $ 315,719

A summary of the interest expense related to the Company's loans payable to related parties is as follows:

Three months ended
September 30,
Nine months ended
September 30,
2026 2025 2026 2025
Koze LTB $ 46,699 $ 58,136 $ 135,427 $ 222,524
Koze A 29,252 62,349 72,646 153,506
Koze B 106,130 156,655 267,588 681,064
Koze C 5,134 8,818 14,888 41,595
Koze CN 1,961 2,639 5,687 10,865
Mr. Tal LTB 7,190 9,805 19,223 38,436
Mr. Tal CN 4,544 7,211 13,179 32,718
Formosa 31,187 26,459 87,386 75,120
Total $ 232,097 $ 332,072 $ 616,024 $ 1,255,828

A summary of the imputed interest expense related to the Company's loans payable to related parties is as follows:

Three months ended
September 30,
Nine months ended
September 30,
2026 2025 2026 2025
Koze LTB $ 73,123 $ 45,258 $ 212,056 $ 45,258
Koze A 20,913 17,836 88,861 17,836
Koze B 99,026 75,310 350,636 75,310
Koze C 8,038 5,198 23,312 5,198
Koze CN 3,071 1,985 8,906 1,985
Mr. Tal LTB 11,436 7,501 30,278 7,501
Mr. Tal CN 7,116 4,634 20,636 4,634
Formosa 51,634 29,520 144,677 29,520
Total $ 274,357 $ 187,242 $ 879,362 $ 187,242

Royalty payable

Pursuant to the Royalty Agreement, as at September 30, 2026, the royalty amount payable to Koze was $513,129 (CAD $728,047) (December 31, 2025 - $305,492 (CAD $418,707)).

Obligation to issue shares

As at September 30, 2026, the Company has an obligation to issue shares to Mr. Tal and Koze in equal proportions as part of the LTB transaction. The obligation is measured by reference to 454,231,075 common shares at the closing price of the Company's common shares at the reporting date and was valued at $908,462 (December 31, 2025 - $2,166,681). All 100,000 authorized shares of Series C preferred stock are issued and outstanding. Any portion of the obligation required to be settled in Series C preferred shares cannot be settled until the Company's certificate of incorporation is amended to increase the authorized Series C preferred stock, which requires stockholder approval. No such amendment has been approved or filed as of the date of these financial statements. Because a sufficient number of authorized and unissued shares is not available, the obligation is recognized as a liability and measured at fair value at each reporting date.

Liability for right-of-use building

On March 11, 2025, Formosa became a related party upon the appointment of its manager as a director of the Company.

As at September 30, 2026, the liability for right-of-use building was $5,771,851 (December 31, 2025 - $6,034,080).

Under the terms of the agreement, a default occurs if Alberta Ltd. fails to make such payments or lease payments for three consecutive months or for any four months within any rolling six-month period. As collateral for the obligations under the agreement, the Company granted Koze a security interest in all of its ownership interest in Alberta Ltd. The security interest will remain in place until all obligations are fully satisfied. As at September 30, 2026, Alberta Ltd. has failed to make the payments under the agreement and Koze agreed to forbear from exercising its right of ownership interest in Alberta Ltd. until August 31, 2026 (Note 2). The forbearance period expired on August 31, 2026. See Note 9 to the condensed interim consolidated financial statements for events subsequent to period end relating to the forbearance and note maturities. During the three and nine months ended September 30, 2026, the Company recognized interest expense related to rent in default of $177,471 and $508,440, respectively, associated with unpaid lease payments (2025 - $145,858 and $435,600, respectively). As at September 30, 2026, accrued interest related to rent in default was $1,498,368 (December 31, 2025 - $1,037,180).

As at September 30, 2026, lease payments of $5,041,794 were outstanding, which is an event of default under the lease. On an event of default, Formosa may, at its option and by notice, require immediate payment of the current month's rent, the rent for the following three months and all amounts outstanding. No such notice has been given as at the date of this report.

Deferred revenue

As at September 30, 2026, the Company had deferred revenue of $36,298 (December 31, 2025 - $260,561) related to transactions with related parties. The deferred revenue balance represents consideration received in advance for products to be delivered.

Critical accounting estimates

The Company's financial statements and accompanying notes have been prepared in accordance with US GAAP. The preparation of these financial statements requires management to make estimates, judgments, and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management.

In preparing these financial statements, the Company is exposed to the same sources of estimation uncertainty as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

CannaPharmaRx Inc. published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 17, 2026 at 13:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]